Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
- 21 January 2024
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 254, 155142
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute (RC-2022- 2773458)
This publication has 37 references indexed in Scilit:
- Systemic Therapy for Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2017
- Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patientsBioScience Trends, 2017
- The epigenetic landscape of renal cancerNature Reviews Nephrology, 2016
- Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase InhibitorsJournal of Urology, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell CarcinomaEuropean Urology, 2013
- BAP1 loss defines a new class of renal cell carcinomaNature Genetics, 2012
- VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacyCurrent Oncology Reports, 2009
- Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesisMolecular Pathology, 2000
- Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesisGenes, Chromosomes and Cancer, 1998